BioCanRx
Canada's Immunotherapy Network
Le réseau canadien d'immunothérapie

Enabling Studies Program

Advanced preclinical development of AVID200: Preparing for immunotherapy clinical trials

Jan. 31, 2018 to Dec. 31, 2019

Highlights

- AVID200 is an antibody-like drug candidate designed to trap and neutralize TGFß
- Enhances the anti-tumour activity of immune T cells, reduces the growth of tumours, and increases the sensitivity of tumours to other immunotherapies
- AVID200 has the potential to act alone or in combination therapies
- Results of this study will be the production of clinic-ready AVID200 for near-term clinical trial

targeted cancers

Solid tumours and myelofibrosis

This project's goal is to provide the basis for the CMC sections of the AVID200 Canada Clinical Trial Applications (CTAs) that will be submitted to Health Canada.

Project value

$1,927,386

BioCanRx contribution:
$675,000

Biotherapeutics

AVID200, anti-TGFß

Partners

1

FORBIUS

About the project

Cancer immunotherapies have met with unprecedented success over the last decade. However, only 20-40% of patients respond when these drugs are used as single agents. TGFß is a secreted protein that is aberrantly produced by tumours, and which promotes cancer progression mainly by suppressing both the innate and adaptive immune systems.

AVID200 is an antibody-like drug candidate designed to trap and neutralize TGFß with high potency. Dr. Koropatnick and team have shown in several cancer rodent studies that AVID200 is able to enhance the anti-tumor activity of immune T cells, reduce the growth of tumours, and increase the sensitivity of tumours to other immunotherapies. Accordingly, AVID200 is a highly promising new addition to the cancer immunotherapy arsenal. It has the potential to act alone as an immunotherapeutic agent, or to be used in combination with other agents to sensitize tumors to other immunotherapies. This Enabling Study allows the team to complete work that is required prior to clinical testing of a new therapy. The activities will include completing GLP toxicology studies, and Chemistry, Manufacturing and Controls (CMC) activities. This data will provide the basis for submission of a Health Canada Clinical Trial Application (CTA), and will enable the testing of this new therapy in Canadian cancer patients.

AVID200 was developed by Formation Biologics Inc. and assessed pre-clinically in the Koropatnick laboratory. Formation Biologics Inc. has set out a development plan and Gantt chart to bring AVID200 to first-in-human clinical trials within 2 years.

Key investigators

Project Lead:
Dr. James **Koropatnick**

Co-Principal Investigator:
Dr. Trevor **Shepherd**

LAWSON HEALTH RESEARCH INSTITUTE

Western UNIVERSITY · CANADA

Enabling Study Investigators



London
Lawson Health Research Institute,
The University of Western Ontario
Dr. James Koropatnick
Dr. Trevor Shepherd

Montreal
Formation Biologics Inc.
Dr. Maureen O'Connor-McCourt
Dr. Gilles Tremblay

Partners

Forbius
$1,252,386

Key Milestones

April 2018
- Release of a GMP bacth of AVID200 for use in the clinic (go/no go for submitting the CTA to Health Canada)

June 2018
- Approval of the AVID200 CTA by Health Canada (go/no go for proceeding to the clinical trial)

March 2019
- Completion of GLP toxicology studies (go/no go for determining first-in-human dose of AVID200)

The power to kill cancer lies within us.
Let's tell our bodies how.

BioCanRx
Canada's Immunotherapy Network
Le réseau canadien d'immunothérapie